Magnus Jaderberg
Chief Tech/Sci/R&D Officer bij Targovax Oy
Actieve functies van Magnus Jaderberg
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
Targovax Oy
Targovax Oy Pharmaceuticals: MajorHealth Technology Targovax Oy focuses on the development and commercialization of targeted cancer immunotherapy. It is a biotechnology company with novel immunotherapy platform that is based on engineered oncolytic viruses armed with potent immune-stimulating transgenes. The firm's products induce a tailored response by the immune system directed at each patient’s unique cancer cells. The company was founded by Pekka Ilmari Simula and Antti Vuolanto in 2009 and is headquartered in Helsinki, Finland. | Chief Tech/Sci/R&D Officer | - | - |
King's College (Pennsylvania) | Corporate Officer/Principal | - | - |
Karolinska Institutet | Corporate Officer/Principal | - | - |
The Royal College of Physicians | Corporate Officer/Principal | - | - |
Loopbaan van Magnus Jaderberg
Eerdere bekende functies van Magnus Jaderberg
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | - | - |
CIRCIO HOLDING ASA | Chief Tech/Sci/R&D Officer | - | - |
Statistieken
Internationaal
Verenigde Staten | 3 |
Zweden | 2 |
Verenigd Koninkrijk | 2 |
Operationeel
Corporate Officer/Principal | 4 |
Chief Tech/Sci/R&D Officer | 2 |
Sectoraal
Health Technology | 4 |
Consumer Services | 4 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
Beursgenoteerde bedrijven | 2 |
---|---|
BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
CIRCIO HOLDING ASA | Health Technology |
Bedrijven in privébezit | 1 |
---|---|
Targovax Oy
Targovax Oy Pharmaceuticals: MajorHealth Technology Targovax Oy focuses on the development and commercialization of targeted cancer immunotherapy. It is a biotechnology company with novel immunotherapy platform that is based on engineered oncolytic viruses armed with potent immune-stimulating transgenes. The firm's products induce a tailored response by the immune system directed at each patient’s unique cancer cells. The company was founded by Pekka Ilmari Simula and Antti Vuolanto in 2009 and is headquartered in Helsinki, Finland. | Health Technology |
- Beurs
- Insiders
- Magnus Jaderberg
- Ervaring